Molecular Pharmacology USA Ltd. has released an amendment to their quarterly report for the period ending March 31, 2025. The report, originally published on May 12, 2025, has been reformatted to enable machine readability, but it is important to note that the contents of this amendment have not been reviewed by the OTC Markets Group, which disclaims all responsibility for the information contained within. The financial statements and other financial information provided in this disclosure have been restated to fairly present the financial condition, results of operations, and cash flows of the company as of the periods presented. The company's Principal Executive Officer and Principal Financial Officer, Xin Shi, certified that the disclosure statement does not contain any untrue material facts or omissions. As of March 31, 2025, the number of outstanding shares of the company's common stock remained unchanged from December 31, 2024, at 999,553,740.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.